At a glance
- Originator Sankyo
- Class Antibacterials
- Mechanism of Action RNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 15 Jul 1997 New profile
- 15 Jul 1997 Preclinical development for Bacterial infections in Japan (Transurethral)